AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer

AstraZeneca (AZN, AZN.L) said results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi or durvalumab demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma or HCC who had not received prior systemic therapy and were not eligible for localised treatment.